untreated adult acute myeloid leukemia
Information
- Disease name
- untreated adult acute myeloid leukemia
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02085408 | Active, not recruiting | Phase 3 | Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | February 4, 2011 | October 2024 |
| NCT02159495 | Active, not recruiting | Phase 1 | Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | December 15, 2015 | December 15, 2024 |
| NCT03009240 | Active, not recruiting | Phase 1 | Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | August 21, 2017 | December 15, 2024 |
| NCT00008177 | Completed | Phase 1 | Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | July 27, 1999 | December 15, 2010 |
| NCT00012376 | Completed | Phase 1 | Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer | March 2001 | |
| NCT00014235 | Completed | N/A | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | December 2000 | |
| NCT00016016 | Completed | Phase 1/Phase 2 | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia | February 2001 | |
| NCT00025415 | Completed | Phase 1 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | August 2001 | |
| NCT00027820 | Completed | Phase 1/Phase 2 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | August 2001 | September 5, 2004 |
| NCT00027872 | Completed | Phase 2 | Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | October 2001 | January 2009 |
| NCT00039117 | Completed | Phase 1 | Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia | April 2002 | |
| NCT00078858 | Completed | Phase 1/Phase 2 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | September 2003 | |
| NCT00079378 | Completed | Phase 1 | Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | February 2004 | |
| NCT00085124 | Completed | Phase 3 | Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia | December 2003 | |
| NCT00089011 | Completed | Phase 2 | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer | April 2004 | July 2018 |
| NCT00093418 | Completed | Phase 2 | S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia | September 2004 | |
| NCT00095797 | Completed | Phase 1 | XK469R in Treating Patients With Refractory Hematologic Cancer | October 2004 | |
| NCT00096122 | Completed | Phase 1/Phase 2 | Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | September 2004 | February 2010 |
| NCT00098826 | Completed | Phase 1 | SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes | December 2004 | |
| NCT00101296 | Completed | Phase 1 | Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | October 2004 | |
| NCT00112853 | Completed | Phase 1 | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | March 2005 | |
| NCT00275080 | Completed | Phase 1 | Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia | February 2006 | August 2014 |
| NCT00278330 | Completed | Phase 1 | Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia | January 2006 | |
| NCT00301938 | Completed | Phase 1 | 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes | December 2005 | |
| NCT00305773 | Completed | Phase 2 | Vorinostat in Treating Patients With Acute Myeloid Leukemia | January 2006 | January 2010 |
| NCT00313586 | Completed | Phase 2 | Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | August 2006 | July 2013 |
| NCT00352365 | Completed | Phase 2 | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia | June 2006 | July 1, 2011 |
| NCT00357032 | Completed | Phase 2 | PXD101 in Treating Patients With Acute Myeloid Leukemia | May 2006 | July 2010 |
| NCT00383474 | Completed | Phase 1 | Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase | August 2006 | June 2012 |
| NCT00407966 | Completed | Phase 2 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | October 2006 | November 2009 |
| NCT00416598 | Completed | Phase 2 | Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia | November 15, 2006 | December 1, 2016 |
| NCT00445744 | Completed | N/A | Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | December 2006 | June 2013 |
| NCT00459212 | Completed | Phase 1 | GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia | March 2007 | |
| NCT00462605 | Completed | Phase 2 | MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia | April 2007 | March 2011 |
| NCT00475150 | Completed | Phase 2 | Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | May 2008 | March 2012 |
| NCT00492401 | Completed | Phase 2 | Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia | May 2007 | October 2014 |
| NCT00602771 | Completed | Phase 2 | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia | January 2008 | October 2011 |
| NCT02129101 | Completed | Phase 1 | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | May 2014 | October 25, 2019 |
| NCT00003934 | Completed | Phase 3 | Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia | June 1999 | |
| NCT00006363 | Completed | Phase 3 | Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia | November 2000 | |
| NCT01567059 | Completed | Phase 2 | Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | May 2012 | June 2013 |
| NCT01588015 | Completed | Phase 1 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | October 29, 2012 | February 2, 2024 |
| NCT01798901 | Completed | Phase 1 | AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia | September 17, 2013 | February 19, 2015 |
| NCT01802333 | Completed | Phase 3 | Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia | February 12, 2013 | June 15, 2017 |
| NCT01804101 | Completed | N/A | Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia | May 7, 2013 | January 10, 2017 |
| NCT01806571 | Completed | Phase 2 | Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | March 12, 2015 | November 30, 2019 |
| NCT01822015 | Completed | Early Phase 1 | Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | March 15, 2013 | December 12, 2019 |
| NCT01831232 | Completed | N/A | Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | May 2013 | January 2016 |
| NCT01839240 | Completed | Phase 1 | Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia | June 6, 2012 | August 16, 2019 |
| NCT01869777 | Completed | N/A | Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia | July 2013 | May 2020 |
| NCT02044796 | Completed | Phase 1/Phase 2 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | January 23, 2014 | April 16, 2018 |
| NCT02093403 | Completed | Phase 1 | Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | March 2014 | November 26, 2016 |
| NCT02096055 | Completed | Phase 2 | Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | April 4, 2014 | November 24, 2020 |
| NCT02121418 | Completed | N/A | Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm | June 2014 | February 14, 2018 |
| NCT02122081 | Completed | Phase 1 | Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | July 27, 2015 | September 6, 2022 |
| NCT00003190 | Completed | Phase 3 | Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia | January 1998 | |
| NCT02144675 | Completed | Phase 2 | Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia | January 2009 | April 26, 2016 |
| NCT02323607 | Completed | Phase 1 | Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations | January 12, 2016 | July 12, 2018 |
| NCT02581917 | Completed | Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia | April 21, 2017 | April 30, 2022 | |
| NCT02583893 | Completed | Phase 2 | Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia | October 7, 2015 | May 17, 2023 |
| NCT02666950 | Completed | Phase 2 | WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | May 5, 2017 | October 17, 2018 |
| NCT02921061 | Completed | Phase 1/Phase 2 | Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | November 17, 2016 | October 24, 2018 |
| NCT00703300 | Completed | Phase 1 | Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia | June 2008 | October 2014 |
| NCT00742625 | Completed | Phase 1/Phase 2 | Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | September 2008 | December 2012 |
| NCT00795002 | Completed | Phase 2 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | November 2008 | September 2012 |
| NCT01031368 | Completed | Phase 1 | Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia | December 2009 | October 24, 2012 |
| NCT01041443 | Completed | Phase 1 | 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | December 2009 | October 2013 |
| NCT01093573 | Completed | Phase 1/Phase 2 | Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia | July 2009 | May 5, 2017 |
| NCT01101880 | Completed | Phase 2 | Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm | August 2010 | July 2017 |
| NCT01130506 | Completed | Phase 1 | Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | May 17, 2010 | |
| NCT01132586 | Completed | Phase 1 | Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | May 2010 | January 2014 |
| NCT01141725 | Completed | Phase 1/Phase 2 | Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS | September 2010 | November 2012 |
| NCT01273766 | Completed | Phase 2 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | January 2011 | December 2014 |
| NCT01307579 | Completed | Phase 3 | Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia | April 4, 2011 | June 30, 2020 |
| NCT01349972 | Completed | Phase 2 | Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | April 2011 | May 2014 |
| NCT01361464 | Completed | Phase 2 | Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia | May 2011 | November 2014 |
| NCT01519596 | Completed | N/A | Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy | October 2012 | February 5, 2017 |
| NCT01555268 | Completed | Phase 1 | Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia | October 31, 2011 | August 3, 2016 |
| NCT02115295 | Recruiting | Phase 2 | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia | May 19, 2014 | May 31, 2026 |
| NCT00801489 | Recruiting | Phase 2 | Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | April 4, 2007 | December 30, 2024 |
| NCT02835222 | Recruiting | Phase 2 | Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients | February 2, 2018 | June 2025 |
| NCT01564277 | Terminated | Phase 2 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | September 29, 2011 | May 28, 2016 |
| NCT02029417 | Terminated | Phase 2 | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | July 2014 | December 2015 |
| NCT01521936 | Terminated | Phase 2 | Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy | December 2011 | June 2015 |
| NCT01907815 | Terminated | Phase 2 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia | October 2013 | January 2016 |
| NCT00673153 | Terminated | Phase 2 | Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | March 2008 | |
| NCT00387426 | Terminated | Phase 2 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | September 2006 | February 2009 |
| NCT01044745 | Terminated | Phase 2 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | December 10, 2009 | October 10, 2017 |
| NCT01801046 | Terminated | Phase 1 | Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia | March 6, 2013 | August 20, 2017 |
| NCT00096148 | Terminated | Phase 2 | Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | October 2004 | |
| NCT02634827 | Terminated | Phase 2 | Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation | December 30, 2015 | June 12, 2018 |
| NCT02105116 | Terminated | N/A | AML Therapy With Irradiated Allogeneic Cells | February 2014 | December 16, 2015 |
| NCT01260714 | Terminated | Phase 1 | Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia | December 2010 | June 2015 |
| NCT02381548 | Terminated | Phase 1 | Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia | August 18, 2015 | May 23, 2018 |
| NCT01849276 | Terminated | Phase 1 | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML | March 11, 2015 | January 21, 2016 |
| NCT00049582 | Terminated | Phase 1 | Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | September 2002 | |
| NCT01876953 | Terminated | Phase 1/Phase 2 | Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia | September 13, 2013 | April 25, 2018 |
| NCT01690065 | Unknown status | Phase 2 | Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML | September 2012 | December 2019 |
| NCT01633099 | Unknown status | Phase 3 | Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients | May 2012 | July 2016 |
| NCT02472626 | Withdrawn | Phase 1/Phase 2 | 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | December 2015 | July 2016 |